Immunocore obtains FDA blessing for Kimmtrak Kimmtrak is the first TCR therapeutic, the first bispecific T cell engager to treat a solid tumor and the first and only therapy for the treatment of unresectable or metastatic uveal melanoma to be approved by the FDA. FDA approves new indication of GSK’s NucalaThe approval allows for at-home administration in patients aged 6 to 11 years old with severe eosinophilic asthma. Allergan obtains FDA green light for Vuity Vuity is the first eye drop approved by the Food and Drug Administration to treat presbyopia, the company said. AbbVie obtains FDA approval for new Skyrizi indication Skyrizi is now approved to treat adults with active psoriatic arthritis, a systemic inflammatory disease that affects the skin and joints. Idorsia obtains FDA nod for Quviviq Idorsia's Quviviq provides a treatment for adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. ParaPro offers Natroba for new indication Natroba provides a topical treatment for scabies infestations in adult and pediatric patients four years of age and older. AbbVie obtains FDA nod for new indication of Rinvoq Rinvoq is now approved for the treatment of moderate to severe atopic dermatitis in adults and children aged 12 years old and older whose disease did not respond to previous treatment. Glenmark Specialty S.A. receives FDA green light for Ryaltris Ryaltris will be marketed and distributed through Glenmark’s partner Hikma Specialty. ViiV Healthcare receives FDA OK for Apretude Apretude is the first and only long-acting injectable option for HIV prevention, the company said. FDA gives Janssen green light for 2 new indications of Xarelto Xarelto is available as both an oral tablet and oral suspension formulation for use in children age 18 years old and younger. First Previous 14 15 16 17 18 Next Last
